Given the very real life and death risks of clinical decision-making, researchers and policymakers are taking steps to ensure AI models are safe, secure and trustworthy - and that their use will lead to improved outcomes.
The research team, led by Professor Masaru Enomoto of the Graduate School of Medicine at Osaka Metropolitan University, fed identical clinical questions and literature selection criteria to two generative AIs; ChatGPT and Elicit.